Pilot Study Using Advanced Diffusion MRI to Tell Tumor Growth Apart From Pseudoprogression in Glioblastoma and Brain Metastasis Patients

What this Trial Is About

Researchers are evaluating advanced diffusion-weighted MRI ADW-MRI to see if it can better distinguish true tumor progression from pseudoprogression in patients with glioblastoma or brain metastases. This pilot study aims to assess the feasibility of using ADW-MRI alongside standard follow-up MRI scans to improve detection accuracy. The study also examines how ADW-MRI results relate to tissue changes and damage in the central nervous system. Participants who have histopathologically confirmed glioblastoma or brain metastases with suspected tumor progression after first-line therapy and are candidates for elective surgical resection will undergo ADW-MRI before surgery. This advanced MRI technique adds about 30 minutes to the routine MRI exam and offers more sensitive detection of subtle tissue changes. If surgery occurs, the removed tissue will be analyzed and compared to the ADW-MRI findings. During the study, patients will receive the additional ADW-MRI scan preoperatively, and if surgery is performed, the tissue will be studied histopathologically. Researchers will correlate MRI results with tissue analysis to understand the techniques accuracy. The primary outcome is the correlation between ADW-MRI findings and histopathological results, assessed once at baseline. Participants will be monitored through their standard clinical care with no masking or placebo involved.

Advanced Diffusion MRI to Differentiate Tumor Recurrence From Pseudoprogression in Patients With Glioblastoma and Brain Metastases